{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004333","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-06-29T11:06:42+00:00","discovered_at":"2026-06-29T11:10:00.267568+00:00","generated_at":"2026-06-29T11:10:24.936308+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst shuts internal discovery, closes Birmingham facility; navenibart Phase 3 enrollment complete; guidance improved","bullets":["Board approved discontinuation of internal discovery programs and closure of Birmingham, AL facility by end 2026.","Phase 3 ALPHA-ORBIT for navenibart (HAE) enrollment completed; top-line data expected Q3 2027.","Resolved manufacturing delay for ORLADEYO oral pellets; product available early August 2026.","2026 non-GAAP operating expense guidance lowered to $420-440M from $450-470M; revenue guidance reaffirmed at $635-660M.","BCX17725 (Netherton syndrome) Phase 1 Part 4 dosing ongoing; proof-of-concept data expected year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004333","json":"https://secwatch.observer/filing/0001171843-26-004333.json","markdown":"https://secwatch.observer/filing/0001171843-26-004333.md","text":"https://secwatch.observer/filing/0001171843-26-004333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/0001171843-26-004333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:10:24.936308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}